Terms: = Germ cell tumor AND B2M, P61769, 567, ENSG00000166710 AND Clinical Outcome
3 results:
1. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
2. Immune-Related tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for clinical outcome and Treatment Decisions.
Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS
Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629
[No Abstract] [Full Text] [Related]
3. Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (b2m) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A.
Martinetti A; Seregni E; Belli F; Mazzocchi A; Agresti R; Cascinelli N; Greco M; Bombardieri E
Anticancer Res; 1998; 18(3B):2027-30. PubMed ID: 9677461
[TBL] [Abstract] [Full Text] [Related]
